DGNews
Most ocular adverse effects associated with bevacizumab therapy for exudative age-related macular degeneration (AMD) resolve within 2 months following therapy, researchers reported at the Association for Research in Vision and Ophthalmology (ARVO) 2009 Annual Meeting.